

„Give Life a Chance through Cancer Immunotherapy”

Esély az életnek. Új Rákellenes Immunterápiák - Szakmai Program

Venue: National Institute of Oncology, Budapest **Time:** 9th - 10th September 2016 (10.00– 18.00)

9th September Morning session: 10.00 – 13.30 (Eckhardt Lecture Hall, General Opening: 10.00 – 11.00)

Welcome and Greetings: "Building the Bridges for Cancer Immunotherapy" (Hungarian Fulbright Alumni representative and members and Hungarian American Fulbright Commission / US Embassy representative)

Opening remarks: Prof Dr Lisa H. Butterfield, Ph.D. Vice president and upcoming president of Society for Immunotherapy of Cancer (SITC) and World Immuno Council (WIC) leadership, Director, UPCI Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, "The 2015-2016 SITC Immunotherapy Biomarkers Task Force"

Welcome lecture: Prof Dr Mária Gődény, MD, PhD, Fulbrighter, Department Head of Radiodiagnostics, National Institute of Oncology "The increasing role of imaging in cancer care."

Welcome lecture: Dr Beatrix Kotlan, PhD Conference Chair, Fulbrighter: Dept. of Molecular Immunology and Toxicology, National Institute of Oncology "The impact of Fulbright grant for translational research"

Opening lecture: Prof Dr Gabriella Liszky, MD, PhD, Conference Chair, Head of Oncoteam, and Department of Oncodermatology, National Institute of Oncology: "Új immunterápiás lehetőségek melanómában" (New immunotherapeutic strategies in melanomas – in the National Institute of Oncology)

11.30 – 11.55. COFFEE break

12.00: **Immunotherapy ROUND TABLE discussion. Chair:** *Prof Dr Gabriella Liszky, MD, PhD, Conference Chair, Challenges for choosing the acceptable therapy. Combination therapies*

12.45: *Guided educational visit to the Department of Radiodiagnostics at the National Institute of Oncology Prof Dr Mária Gődény, MD, PhD, Az Országos Onkológiai Intézet Radiodiagnosztikai Osztályának bemutatása.*

13.30 – 14.15. LUNCH break

**9th September Afternoon session: 14.15 – 18.00. (Eckhardt Lecture Hall/ National Institute of Oncology):
The mosaic of cancer immunotherapy**

14.15: *Prof Dr Lisa H. Butterfield, Ph.D. Vice President, Upcoming President of Society for Immunotherapy of Cancer (SITC) and World Immuno Council (WIC) leadership. Professor of Medicine, Surgery and Immunology, Director, UPCI Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, "Immune Modulation by Alpha Fetoprotein"*

14.40: *Prof Dr Yehuda Shoenfeld, MD, FCs, FACS Head of Zabludowicz Center for Autoimmune Diseases of Sheba Medical Center, Tel-Hashomer, Israel, Fulbrighter, "Adjuvant, autoimmunity and lymphoma –a continuum of a process"*

15.05: *Prof Dr Jean Luc Teillaud, PhD, DSc, Director at Centre de Recherche des Cordeliers/ INSERM, Paris, France, "The vaccinal effect of anti-tumor antibodies: the CD20 case".*

15.30: *Prof Dr Mepur H Ravindranath, M.Sc., Ph.D., Former Fulbright Fellow, Research Scientist and Director at Terasaki Foundation Laboratory Los Angeles, CA, USA: HLA-E mediated Cancer Progression and development of HLA-E monospecific monoclonal antibodies with diagnostic and anti-tumor therapeutic potential.*

15.55 – 16.20. COFFEE break

16.20: *Prof Dr Zoltan Ivics, PhD, DSc*, Head of Division of Medical Biotechnology Paul Ehrlich Institute, Langen, Germany. "The promises and challenges of genetically engineered cells for advanced therapies"

16.40: *Prof Dr Peter Zavodszky, PhD, FCS, FACS*, Head of Innovation Foundation, Hungary, Research Centre for Natural Sciences of the Hungarian Academy of Sciences, MTA, TTK, Budapest, "Immunotherapy and the immunology beyond. Revealing the facts about lectins"

17.00: *Dr Peter Kelemen, MD*, Centre of Surgical Oncology, National Institute of Oncology. "Oncoplastic breast conserving surgery versus conventional breast conserving surgery. Long term retrospective analysis of 350 cases"

17.20: *Dr Akos Savolt MD, PhD*, Centre of Surgical Oncology, National Institute of Oncology. "Optimal Treatment of the Axilla, Surgery of Radiotherapy. Long term results of a prospectiv randomized study"

17.40: *Prof Dr Janos Hunyadi, MD, DSc*, National Institute of Oncology, and University of Debrecen, Hungary, "A dendritikus sejtek, mint új immunterápiás lehetőségek előőrsei "(Dendritic cells in the forefront of new immunotherapeutics).

10th September 2016, Morning session: 10.00 – 13.00 (Eckhardt Lecture Hall/ National Institute of Oncology): Immune system`s involvement in cancer therapy

10.00: *Prof Dr Herve W Fridman, MD, DSc*, Professor of Immunology and Vice-Dean at the Medical School Paris Descartes, Director at Centre de Recherche des Cordeliers/ INSERM, Paris France: "Integrating tumor microenvironments with cancer molecular classifications"

10.25: *Prof Dr Jozsef Timar, MD, PhD, DSc*, Director of Pathology Institute II, Semmelweis University, Budapest, Hungary. *Fulbrighter* "Predictive markers and the immunotherapy of cancer"

10.50: *Prof Dr Catherine Sautes-Fridman, PhD, DSc*, Professor of Immunology at University Paris-Descartes, Head of Cancer, Immunology and Immunopathology department Cordeliers Research Center, UMR, Pierre and Marie Curie University, Paris, France "Immune-based identification of patients with high risk of progression in clear cell Renal Cell Carcinoma"

11.15: *Prof Dr Eytan Barnea, MD, FCOG*, Chief Scientist BioIncept, LLC, Chairman and Founder of the Society for the Investigation of early Pregnancy, Cherry Hill, NJ, USA, "Potential therapy for immune-based cancers".

11.40 – 12.00: COFFEE break

12.00: *Prof Dr Nicola Mozzillo, MD, PhD* : Director of Melanoma Surgery, National Cancer Institute of Naples, Naples, Italy. "Immunotherapy meets electrotherapy. New achievements in it."

12.25: *Dr Katalin Czirbesz & Dr Gorka Eszter, MD*: Oncodermatology Department, National Institute of Oncology, "Experiences with Electrochemotherapy in the National Institute of Oncology", Budapest

12.45: *Dr Andrea Ladanyi, PhD*, Tumor immunology, Surgical and Molecular Tumorpathology, National Institute of Oncology. "Újdonságok és kérdések a tumorimmunológiában" (Advances and questions in tumor immunology)

**13.05. – 13.35. Újabb lehetőségek az immunonkológia területén
(Further advances in Immuno-Oncology)** (Symposium sponsored by Bristol-Myers Squibb Kft.)

13:05-13:20 A kombinált nivolumab+ipilimumab kezelés szerepe melanomában (The role of the combined nivolumab+ipilimumab therapy in melanoma)

Professor Dr Gabriella Liszkay, MD, PhD

13:20-13:35 Új perspektívák a veserák kezelésében az immunterápia segítségével (New perspectives with immunotherapy in renal cell carcinoma)

Dr. Fruzsina Gyergyay, MD, PhD

13.35 – 14.55. *Introducing the Oncodermatology Department of National Institute of Oncology with Professor Dr Gabriella Liskay, MD, PhD, Conference Chair*

13.50. – 14.25. LUNCH break

10th September 2016. Afternoon session: 10.00 – 13.00 (Eckhardt Lecture Hall/ National Institute of Oncology): Harnessing the potentials of tumorimmunology for cancer cure

14.25: *Prof Dr Soldano Ferrone, MD, PhD-DF/HCC*, Professor in Residence of surgery, Harvard Medical School, The Harvard Clinical and Translational Science Center, Boston, USA, “The molecular basis and the clinical significance of HLA antigen defects in malignant cells.”

14.50: *Prof Dr Gabriella Sarmay, PhD, DSc* Research Centre for Natural Sciences of the Hungarian Academy of Sciences, Budapest. “Az immunrendszer kétélű kard – az érem másik oldala” (Immune system: the double-edged sword – The other side of the picture)

15.15: *Prof Dr Miri Blank, PhD, DSc*, Head of Immunology Department at the Zabudowicz Center for Autoimmune Diseases of Sheba Medical Center, Tel-Hashomer, Israel: “Natural human antibodies, IVIG and their potentials for cancer cure”

15.40: *Dr Beatrix Kotlan, PhD, Fulbrighter*, National Institute of Oncology, Novel immunotherapeutic approaches – exceeding our imagination! (Új immunterápiás és génmanipulációs lehetőségek egy karnyújtásnyira tőlünk.)

16.00 – 16.20. COFFEE break

16.20: *Dr Nora Bittner, MD, PhD*, National Institute of Oncology, *President of Hungarian League Against Cancer*, *Conference Chair*: “A tüdőrák immunterápiája és mellékhatásai- eredmények és nehézségek” (Immunotherapeutics for pulmonary cancers – achievements and hardships).

16.45: *Dr Marie-Caroline Dieu-Nosjean, PhD*, Laboratory "Cancer, Immune control and Escape" UMRS 1138 INSERM, Cordeliers Research Centre, Paris, France, “Emergence of Tertiary Lymphoid Structures as a first line of defense against tumors”

17.10: *Prof Dr Andrzej Mackiewicz, MD, PhD, DSc*, Chair of Medical Biotechnology, Poznan University of Medical Sciences, Greater Poland Cancer Centre, BioContract Sp. z o.o. Poznan, Poland, Past President of Polish Immunological Society, “Potential and experience with novel melanoma therapeutic vaccines”

17.35: *Prof Dr Andras Szekacs, PhD, DSc, Fulbrighter*, Director of the Agro-Environmental Research Institute. National Agricultural Research and Innovation Center, Budapest. “Allowed genotoxicity of the chemicals we are exposed to.”

17.55: Team science project: “**Pioneering the trail of cancer Immunotherapy in Hungary**”. Closing remarks.

There might be some changes in the program schedule.

Dr Beatrix Kotlan, PhD
Conference Chair
National Institute of Oncology
kotlanb@netscape.net
+36 1 224 8600/ 3294

Prof Dr Gabriella Liskay, MD, PhD,
Conference Chair
Head of Oncoteam, Department Head of Oncodermatology,
National Institute of Oncology, Budapest
liskay@oncol.hu